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APPENDIX A
U.S. Food and Drug Administration
FDA's Vision
FDA in the year 2000 will be ...
* A strong science-based agency-to accurately detect and assess health
risks, and to set appropriate standards.
* A trusted agency-to enforce the Food, Drug, and Cosmetic Act
fairly, uphold safety standards, and protect consumers.
* An enabling agency-to steward needed products and to promote
public health.
* A collaborative agency-to strengthen ties to scientific, health
provider, and regulatory communities both domestically and internation-
ally.
* A high-performance agency-to capitalize on state-of-the-art informa-
tion and communication technologies and management systems to
enhance performance.
* An employee-valued agency-to recruit, develop and advance
employees equitably, and to position the agency to meet the changing
work force needs of the 21st century.
FDA principally serves the general public in its health and safety mission.
FDA also recognizes its responsibilities to the industries that it regulates and
will work with them in shepherding new technologies to the marketplace.
Thus it strives to maximize public health protection while minimizing
regulatory burden.
1996]
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APPENDIX B
(U.S. Food and Drug Administration)
REINVENTING THE REGULATION OF DRUGS
MADE FROM BIOTECHNOLOGY
President Bill Clinton
Vice President Al Gore
National Performance Review
November 1995
OVERVIEW
INTRODUCTION
In March 1995, President Clinton announced a series of regulatory
reform initiatives designed to reduce the burden of FDA regulations on the
drug and device industries without sacrificing any of the health and safety
protections that the American people rightly expect for these products. The
report, Reinventing Drug and Medical Device Regulations, issued by Vice
President Gore's National Performance Review, announced initiatives that
will streamline the regulation of drugs and medical devices.
Today's report focuses on FDA's efforts to reform the regulation of
biotech drugs used for therapy. The changes outlined in this report represent
the most significant overhaul of the regulation of biotech drugs the FDA has
ever attempted. FDA will in essence harmonize its regulation of biotech
drugs that qualify as "well-characterized," making uniform the requirements
of its two product centers responsible for helping to ensure the safety and
effectiveness of biologic drugs: the Center for Biologics Evaluation and
Research (CBER) and Center for Drug Evaluation and Research (CDER).
According to the biotechnology industry, these changes will save their
companies millions of dollars and cut drug development time by months. At
the same time, the agency believes that these modifications will not diminish
the safety and effectiveness of biotech drugs.
For well-characterized, therapeutic biotechnology-derived drugs-a
definition that includes most biotech drugs-FDA will:
* eliminate CBER's existing requirement that manufacturing facilities be
separately licensed;
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* eliminate the existing policy under which CBER evaluates and releases
individual lots of biotech drugs after the drugs have been approved; and
* replace with one form the 21 different approval application forms for
biotech drugs, blood, vaccines, and other drugs.
For all biologics, including biotech drugs regulated by CBER, FDA will:
* eliminate the current requirement that promotional labeling be
-approved prior to the launch of a biologic and for 120 days following its
approval;
* decide within 30 days whether newly submitted information supports
the initiation or continuation of a human investigation that the agency has
put on hold; and
* permit a corporation to designate more than one person to act as a
"Responsible Head" in dealings with CBER.
These and other initiatives described in this report will greatly streamline
the regulation of biotech drugs, harmonize the requirements with respect to
manufacturing, and facilitate the development and marketing of new biotech
drugs.
BACKGROUND
Two FDA operating components regulate drugs: CBER, which regulates
blood, vaccines, human tissues and many drugs derived from living
organisms, principally under the Public Health Service Act, and CDER,
which regulates other drugs under the Federal Food, Drug, and Cosmetic
Act.
The drugs made from living organisms regulated by CBER are subject
to statutory requirements in addition to those governing all other drugs. For
statutory reasons, and historical reasons, the two centers have approached the
regulation of biotech drugs somewhat differently. For example, CBER has
required two separate licenses for every biotech drug that it regulates: (1) a
product license; and (2) an establishment license for each facility in which
the drug is manufactured. CBER has also required "lot-by-lot release" for the
biotech drugs that it regulates, which means that CBER authorizes the release
of individual lots.
The agency is now proposing to harmonize the two centers' policies and
requirements for therapeutic biotech drugs that qualify as "well-charac-
terized," which includes most biotech drugs.
[Vol. 33
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FDA's PROPOSALS FOR REFORM
Elimination of the Requirement for an Establishment License Application
for Most Biotech Drugs
Background: Section 351 of the Public Health Service Act, which is
administered by CBER, requires that biologics be manufactured in establish-
ments holding a license. In addition to the product application, which both
CDER and CBER require, CBER currently requires manufacturers of all
biologics, including the biotech drugs it regulates, to obtain approval of a
separate establishment license application for each facility in which a biologic
is to be manufactured. According to companies that manufacture biotech
drugs, complying with the establishment license application requirement can
cost millions of dollars and delay the submission of an application to the
agency by several months. Thus, the requirement for establishment license
applications places a significant burden both on industry, which must produce
them, and on the agency, which must review them.
Technical advances over the last 15 years have greatly increased
scientists' ability to control the manufacture of many biotech drugs. After
over a decade of experience with these drugs, the agency has found that it
can review the safety, purity, potency, and effectiveness of most biotech
drugs regulated by CBER without requiring a separate establishment license.
Proposal: CBER will eliminate the requirement for submission and
approval of establishment license applications for therapeutic biotech drugs
that are "well-characterized." In place of the establishment license applica-
tion, CBER will evaluate the adequacy of manufacturing facilities by
inspection for compliance with good manufacturing practices and through the
use of a new chemistry, manufacturing, and controls section of a newly
revised product license application. The format and content of the product
license application will be harmonized with a slightly revised new drug
application for the well-characterized biotech drugs regulated by CDER. (The
new drug application revision will consist of the addition of a simple
one-page floor plan sufficient to allow an FDA reviewer to visualize the
production of the drug, but will not require a detailed description of
equipment placement.) CDER and CBER will use the same technical
guidance documents.
The harmonization across centers of the chemistry, manufacturing, and
controls format and content will also reduce the amount of information that
biotech companies will need to provide in the product license application.
For example, in many instances manufacturing facility information will not
be submitted to the agency, but will be reviewed during good manufacturing
practice inspections.
Preapproval inspections for biotech drugs regulated by CBER will
continue to be done jointly by headquarters and field staff. These inspections
will be comparable to the inspections currently conducted for biotech drugs
regulated by CDER. To ensure that inspection procedures for biotech drugs
1996]
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will be consistent across the centers and the field, the FDA will train its
scientists and inspectors using the same principles.
As described in the National Performance Review's report on Reinvent-
ing Drug and Medical Device Regulations, FDA has already begun reducing
requirements for preapproval of manufacturing and site changes. Under this
proposal, manufacturing and site change requirements for biotech drugs will
be harmonized across CBER and CDER. To implement this proposal, the
agency will develop a definition of "well-characterized" biotech drugs. The
agency anticipates that most therapeutic biotech drugs regulated by CBER
will fall within this definition and, therefore, will be exempted from the
requirement to submit and have approved a separate establishment license
application. To refine the agency's definition of well-characterized
biotechnology-derived biologic drugs eligible for these streamlining efforts,
FDA is also sponsoring a public scientific workshop on Dec. 11-13, 1995.
The agency anticipates that the workshop may identify additional product
classes that could be exempted from the establishment license application
requirements.
FDA believes that these changes in regulatory procedures and require-
ments will not diminish the safety, purity, potency, and effectiveness of
biotech drugs. This is because with in-process control and process validation,
the identity of the drugs to which the changes apply can be determined, their
purity can be controlled and quantified, their activity and quantity can be
measured, and both the manufacture and the end-product release specifica-
tions can be validated.
Impact: Companies developing and manufacturing most biotech drugs
regulated by CBER will no longer have to prepare establishment license
applications and submit them to the agency for approval. The amount of
information that companies will need to provide in the product license
application will also be reduced. These proposed changes will get biotech
drugs to market faster and will enable companies to devote more resources
to developing drugs and ensuring that they are manufactured appropriately,
and fewer resources to submitting documentation to the agency. This change
will especially benefit small biotechnology companies that lack experience in
preparing establishment and product license applications. According to
companies, the establishment license application requirement adds substantial-
ly to the cost of biotech drug approval.
These proposed changes will also harmonize the requirements across the
agency concerning a company's ability to contract out manufacture of its
well-characterized therapeutic biotech drugs. These proposals will eliminate
the requirement that each separate contract facility engaging in significant
production steps obtain its own establishment license. Instead, each such
biotech drug will be covered by only one marketing application, which lists
all manufacturing locations, regardless of how many separate companies are
involved in its manufacture.
Implementation and Timeline: Within 30 days, the agency will issue a
proposed rule under which companies manufacturing "well-characterized
[Vol. 33
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biotechnology-derived drugs" would not be required to obtain a separate
establishment license. The proposal will include a definition of
"well-characterized biotechnology-derived drugs," and will allow 30 days for
comment. The agency will publish a final rule 60 days after the close of the
comment period.
Elimination of Lot Release Requirements for Biotech Drugs
Background: Biologics have traditionally been complex mixtures of
substances produced primarily from living organisms, and have been difficult
to define by precise tests. They include vaccines, products made from human
or animal blood, and other products made from a variety of materials.
Because of the inherent variability of these products, each individual lot of
most biologics has been subject to evaluation and testing by FDA.
Historically, the lot release requirement has served an important role in
the regulation of biological drugs and has prevented the distribution of
unacceptable lots. Greater control has been achieved by manufacturers over
the production of biotech drugs through in-process controls, process
validation, and recent advances in analytical techniques. For
well-characterized therapeutic biotech drugs, the agency has found that once
a company has demonstrated its ability to consistently produce acceptable
lots, and has procedures in place that will prevent the release of lots that do
not meet release specifications, it is not necessary for FDA to verify that
each manufactured lot is acceptable for release.
Proposal and Justification: Once a well-characterized therapeutic biotech
drug has been licensed for marketing and its manufacturing process has been
validated, it will not be subject to lot-by-lot release by FDA. The agency will
monitor companies' compliance with the requirement that they assay each lot
and release only those that meet release specifications. In light of the
developments in manufacturing and testing for well-characterized biotech
drugs, FDA's lot-by-lot release is not necessary.
Impact: The elimination of lot-by-lot release of biotech drugs will result
in a significant savings of time and resources for both the industry and the
agency. There will be no significant additional risk to public health because
these drugs are well-characterized and do not warrant direct agency
participation in quality-assurance testing.
Implementation and Timeline: The agency will immediately begin
sending letters to affected companies advising them of the change in the
lot-by-lot release policy. Within 30 days, the agency will issue a notice
describing the elimination of lot-by-lot release for well-characterized
therapeutic biotech drugs.
Harmonized Application Format for All Drugs and Biologics
Background: CBER currently uses 19 different product license applica-
tion forms and a separate establishment license application form. In addition,
19961
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CDER has a separate new drug application form. This is confusing for the
industry.
Proposal and Justification: The agency will consolidate the 21 different
application forms into one. The harmonized form will contain a technical
section on the establishment, which will be applicable only to those biologics
for which establishment application review will continue to be necessary. The
agency also intends to include some elements from the European Community
format in order to facilitate international harmonization of applications.
In addition to a harmonized application form, the technical requirements
and guidance documents will be the same across the agency for
well-characterized therapeutic biotech drugs, regardless of which center
regulates them. Also, the agency will harmonize its procedures regarding
contracting out manufacture of drugs and biologics.
Impact: Companies will be able to provide higher quality submissions.
Time to prepare applications will be reduced because forms will be standard-
ized.
FDA will reduce 21 applications to one application. The standard format
should expedite review by FDA staff and can be used as a basis for
electronic submissions.
Implementation and Timeline: Within 60 days, CBER will make
available a draft form which companies may choose to use for product
license applications for well-characterized therapeutic biotech drugs. Within
six months, FDA will publish a proposed revised application form for all
drugs and biologics.
Elimination of the Preapproval Requirement for Promotional Labeling
Background: CBER currently requires preapproval of promotional
labeling prior to launch of a new biologic and for 120 days following
approval of a new biologic. This is inconsistent with what is required by
CDER, which requires companies to send such information to the agency at
the time the company disseminates it.
Proposal and Justification: CBER will change its current policy that
labeling in connection with the launch of a new product be approved.
Impact: Industry will no longer need to await approval of promotional
labeling prior to disseminating it. Agency resources will be freed up to
accomplish other review activities.
Implementation and Timeline: Effective immediately, the agency will no
longer require preapproval of promotional labeling. The agency will
promptly issue a Federal Register notice announcing this new policy.
Agency Responses to Data Submitted Regarding Clinical Holds
Background: Companies or individuals that intend to study investigation-
al drugs or biologics in humans must first submit an investigational new drug
(IND) application to the agency. They may proceed with the study 30 days
[Vol. 33
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after the agency receives the application, unless FDA puts the study on
clinical hold. A clinical hold is a directive issued by FDA that prevents the
clinical study from proceeding. Thus, a researcher or company that intends
to begin testing a new biologic in humans, or is in the process of testing a
new biologic in humans, may not begin or continue the study until FDA
releases the clinical hold. Currently, FDA has no internal requirements
regarding how much time it may take to evaluate data submitted by the
sponsor in response to the clinical hold. While the agency has generally
responded in a timely manner, sponsors would like the predictability
engendered by an agency commitment to respond within a specified time
frame.
Proposal and Justification: FDA will commit itself to review and respond
to data submitted in response to a clinical hold within 30 days of receiving
the submission. Unless FDA responds within that period, the investigation
may proceed. FDA believes that the 30-day period will meet the needs of
sponsors, and is within the resource capabilities of the agency.
Impact: The proposed change will prevent delays in agency review of
data submitted in response to a clinical hold on an IND, and thus prevent
unnecessary delays in the start or continuation of clinical studies.
Implementation and Timeline: FDA will publish within six months a
guidance document establishing new procedures for reviewing data submitted
in response to clinical holds on INDs.
Revision of the Requirements for a Responsible
Head for Biological Establishments
Background: Manufacturers of biological products are required to name
a "Responsible Head" who is to exercise control of the manufacturing
establishment in all matters relating to compliance with the regulations and
who is to represent the manufacturer in all dealings with FDA. This
individual must have an understanding of the scientific principles and
techniques related to the manufacture of biological products.
In the past, biological product manufacturers typically were small
companies, such as blood banks, that made products at one location. The
requirement that a single responsible head represent the company was
practical for such small operations. Today, however, manufacturers of
biological products tend to be larger firms with more manufacturing locations
and more complex corporate structures. Most companies do not have one
person with the knowledge to represent a company in all matters, but instead
have several people with expertise in regulatory affairs, manufacturing, and
medical issues.
Proposal and Justification: FDA proposes to revise its requirements for
a "Responsible Head" to allow more flexibility to assign control and
oversight responsibility within a company. The revisions will still ensure the
proper oversight and accountability within a firm, but will conform to the
way biological firms assign responsibilities to their senior experts.
19961
11
authors: Appendices
Published by CWSL Scholarly Commons, 1996
CALIFORNIA WESTERN LAW REVIEW
Impact: Firms will be able to divide management responsibility among
appropriate regulatory, medical, or manufacturing staff. These individuals
will be able to directly communicate with the agency on official matters
related to biological products they manufacture.
Implementation and Timeline: FDA will publish a proposal to revise the
regulation within nine months.
(U.S. Food and Drug Administration)
(What's New)
Here are links to new items FDA has made available on its Internet site
during the past four weeks. Also check the FDA News page for additional
new information, including press releases, Congressional testimony, and
other public statements.
Approval of New Drugs in the United States Comparison With the
United Kingdom, Germany and Japan. David A. Kessler MD, JD; Arthur E.
Hass; Karyn L. Feiden; Murray Lumpkin, MD; Robert Temple, MD.
Originally published in Journal of the American Medical Association,
December 11, 1996 - Vol 276, No. 22
Latest Major Speech: David A. Kessler, M.D., Commissioner of Food
and Drugs-Annual Meeting, Food and Drug Law Institute (Dec. 10, 1996)
Pesticide Residue Monitoring Program Report for 1995
A summary of the results of FDA's pesticide residue monitoring
program for the period Oct. 1, 1994, through Sept. 30, 1995. Selected
findings from the Total Diet Study are also presented.
FDA's Office of Women's Health Web Site
Important information for and about women from FDA and other
sources.
Protection of Human Subjects; Informed Consent Verification-Final
Rule (Nov. 5, 1996)
Protection of Human Subjects; Informed Consent-Final Rule (Oct. 2,
1996)
What's New at the Center for Devices and Radiological Health
What's New at the Center for Drug Evaluation and Research
What's New at the Center for Veterinary Medicine
(Comments) (FDA Home Page)
Last revised Dec. 16, 1996
[Vol. 33
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APPENDIX C
A Guide to Helpful Government Documents on the Internet
Guidance for Industry: Content and Format of Investigational New Drug
Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Character-
ized, Therapeutic, Biotechnology-derived Products
..................... map available on page 134
Demonstration of Comparability of Human Biological Products, Including
Therapeutic Biotechnology-derived Products
..................... map available on page 135
Draft Points to Consider in the Manufacture and Testing of Monoclonal
Antibody Products for Human Use (1994) [PTC MAB.TXT; PTC
MAB.W51]
..................... map available on page 136
Points to Consider in the Manufacture and Testing of Therapeutic Products
for Human Use Derived From Transgenic Animals [PTC TGA.TXT;
PTC TGA.W51]
..................... map available on page 136
Addendum to the Points to Consider in Human Somatic and Gene Therapy
(1991) [GSTA.TXT; GSTA.W51]
..................... map available on page 136
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authors: Appendices
Published by CWSL Scholarly Commons, 1996
CALIFORNIA WESTERN LAW REVIEW
Map of how to access document on the Internet:
Guidance for Industry: Content and Format of Investigational New Drug
Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Character-
ized, Therapeutic, Biotechnology-derived Products:
http://www.fda.gov/
(scroll down to)
Lt . Human Drugs
(scroll down to)
L.. Regulatory Guidance
(scroll down to)
Guidance Documents
(scroll down to)I
I Clinical/Medical
(scroll down to and get)
L-. Th,
Format of Investiga-
tional New Drug
Applications (INDs)
For Phase 1
[Vol. 33
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Map of how to access document on the Internet:
Demonstration of Comparability of Human Biological Products, Including
Therapeutic Biotechnology-derived Products
http://www.fda.gov/
(scroll down to)
t Human Drugs
(scroll down to)
t Regulatory Guidance
(scroll down to)
L.. Guidance Documents
(scroll down to)
L._ Microbiology
(scroll down to and get)
Demonstration of
Comparability of
Human Biological
Products, Including
Therapeutic Bio-
technology-derived
Products
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Map of how to access document on the Internet:
Draft Points to Consider in the Manufacture and Testing of Monoclonal
Antibody Products for Human Use (1994) [PTC MAB.TXT; PTC
MAB.W51]
Points to Consider in the Manufacture and Testing of Therapeutic Products
for Human Use Derived From Transgenic Animals [PTC TGA.TXT;
PTC TGA.W51]
Addendum to the Points to Consider in Human Somatic and Gene Therapy
(1991) [GSTA.TXT; GSTA.W51]
http://www.fda.gov/
(scroll down to)
L.. Biologics
(scroll down to and get)
Draft Points to Consider in the Manufacture
and Testing of Monoclonal Antibody Products for
Human Use (1994) [PTC MAB.TXT; PTC
MAB.W51]
Points to Consider in the Manufacture and
Testing of Therapeutic Products for Human Use
Derived From Transgenic Animals [PTC TGA.TXT;
PTC TGA.W51]
Addendum to the Points to Consider in
Human Somatic and Gene Therapy (1991)
[GSTA.TXT; GSTA.W51]
[Vol. 33
16
California Western Law Review, Vol. 33 [1996], No. 1, Art. 12
https://scholarlycommons.law.cwsl.edu/cwlr/vol33/iss1/12
APPENDICES
APPENDIX D
Additional Resources on the Internet
BioData
http://www.biodata.com
BioMolecular Engineering Research Center
gopher://bmerc-gopher.bu.edu:70/1
BIO Online
http://www.bio.com
BioSpace
http://www.biospace.com
CBER FTP subdirectory
ftp://cdv2.cder.fda.gov/cber
CDER FTP site
ftp://cdv2.cder.fda.gov
Centers for Disease Control Web server
http://www.cdc.gov/
Center for Food Safety and Nutrition
http://vm.cfsan.fda.gov
FDA BBS
telnet://fdabbs.fda.gov; login:bbs
FDA Web site
http://www.fda.gov/fdahomepage.html
Federal Register and U.S. Code through GPO
telnet://librotl.lib.unc.edu; login: LIBRARY
Federal Register
http://gopher.nara.gov:70/1/register
Government Printing Office
http://www.access.gpo.gov/
HUM-MOLGEN - Communication Forum in Human Molecular Genetics
http://www.informatik.uni-rostock.de/HUM-MOLGEN/hum-mol.html
1996]
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Human Genome Resources
gopher://marvel.loc.gov:70/1 1/global/med/med/genome
Immunology Home Page
http://golgi.harvard.edu/biopages/immuno.htm
Intellectual Property Policies
http://infonet.welch.jhu.edu/policy/intellectualpropguide/som-intpol.html
Library of Congress gopher server
gopher://marvel.loc.gov/
Library of Congress Web server
http://Icweb.loc.gov/
National Center for Toxicological Research (NCTR)
http://www.fda.gov/nctr
Nest Group Molecular Biology WVVWW Resources
http://world.std.com/ - nestgrp/molbiol.html
Patent and Trademark Office Web site
http://www.uspto.gov/
Patent Guidance Information
http://sunsite.unc.edu/patents/intropat.htrnl
PharmWeb
http://www.mcc.ac.uk/pharmweb/
RAinfo - The Regulatory Affairs Information Home Page
http://www.nando.net/ads/ckbus/RAinfo/reglinkl.htm
The National Center for Biotechnology Information
http://www.ncbi.nlm.nih.gov/
The World Wide Web Virtual Libary: Biotechnology
http://www.cato.com/interweb/cato/biotech/
US EPA Rules, Regulations and Legislation
http://www.epa.gov/Rules.html
U.S. Patent Office Archives
http://town.hall.org/cgi-bin/srch-patent
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